Long-term disease stabilization following treatment with erlotinib in heavily pretreated patients with wild-type epidermal growth factor receptor non-small-cell lung carcinoma: Two case reports

Nelson V, Ziehr J, Agulnik M and Johnson M: Afatinib: Emerging next-generation tyrosine kinase inhibitor for NSCLC. Onco Targets Ther. 6:135–143. 2013.PubMed/NCBI

Köhler J and Schuler M: Afatinib, erlotinib and gefitinib in the first-line therapy of egfr mutation-positive lung adenocarcinoma: A review. Onkologie. 36:510–518. 2013. View Article : Google Scholar : PubMed/NCBI

Health Quality Ontario, . Epidermal Growth Factor Receptor Mutation (EGFR) testing for prediction of response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) drugs in patients with advanced non-small-cell lung cancer: An evidence-based analysis. Ont Health Technol Assess Ser. 10:1–48. 2010.

Shepherd FA, Pereira J Rodrigues, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI

Goldstraw P: Staging Manual in Thoracic Oncology. Editorial Rx Press; Orange Park, FL: 2009, View Article : Google Scholar

Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al: EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004. View Article : Google Scholar : PubMed/NCBI

Karam I and Melosky B: Response to second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer: Make no assumptions. Curr Oncol. 19:42–46. 2012. View Article : Google Scholar : PubMed/NCBI

Dudek AZ, Kmak KL, Koopmeiners J and Keshtgarpour M: Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer. 51:89–96. 2006. View Article : Google Scholar : PubMed/NCBI

Schumann C, Heigener D, Dittrich I, Abenhardt W, Dederke B, Duell T, et al: Long term benefit from erlotinib treatment is independent of prognostic factors and therapeutic response (abstract 9146). Eur J Cancer. 7:12009.

Polychronidou G and Papakotoulas P: Long-term treatment with erlotinib for EGFR wild-type non-small cell lung cancer: A case report. Case Rep Oncol. 6:189–196. 2013. View Article : Google Scholar : PubMed/NCBI

Jeong HS, Jones D, Liao S, Wattson DA, Cui CH, Duda DG, Willett CG, Jain RK and Padera TP: Investigation of the lack of angiogenesis in the formation of lymph node metastases. J Natl Cancer Inst. 107(pii): djv1552015. View Article : Google Scholar : PubMed/NCBI

Markiewicz A, Książkiewicz M, Seroczyńska B, Skokowski J, Szade J, Welnicka-Jaskiewicz M, Wełnicka-Jaśkiewicz M and Zaczek AJ: Heterogeneity of mesenchymal markers expression-molecular profiles of cancer cells disseminated by lymphatic and hematogenous routes in breast cancer. Cancers. 5:1485–1503. 2013. View Article : Google Scholar : PubMed/NCBI

Augustin A, Lamerz J, Meistermann H, Colling S, Scheiblich S, Hermann JC, Duchateau-Nguyen G, Tzouros M, Avila DW, Langen H, et al: Quantitative chemical proteomics profiling differentiates erlotinib from gefitinib in EGFR wild-type non-small cell lung carcinoma cell lines. Mol Cancer Ther. 12:520–529. 2013. View Article : Google Scholar : PubMed/NCBI